Marc Vidal

First Person | Marc Vidal Courtesy of The Marc Vidal Lab In 1996, Marc Vidal, proteomic cartographer and coinventor of the reverse two-hybrid system, couldn't find work that paid more than a postdoc's salary. He survived on a National Institutes of Health grant and the good graces (if not the prescience) of Harvard University cell biologist Ed Harlow, who believed in Vidal's vision to map protein to protein and let the young Belgian work in his lab. The ideas weren't fashionable, Vida

| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

In 1996, Marc Vidal, proteomic cartographer and coinventor of the reverse two-hybrid system, couldn't find work that paid more than a postdoc's salary. He survived on a National Institutes of Health grant and the good graces (if not the prescience) of Harvard University cell biologist Ed Harlow, who believed in Vidal's vision to map protein to protein and let the young Belgian work in his lab. The ideas weren't fashionable, Vidal says. "Fellowship applications, forget it. Jobs in academia, forget it," recalls Vidal, now 41. "The reductionist approach was fantastic in terms of careers."

Presently at the Dana-Farber Cancer Institute in Boston, Vidal stresses that he is not complaining. "It's important for young people... to commit yourself to your own passion, and what you develop has a chance to become the next fashion."

How did you survive? I had to fight and scream. I went to NIH; they did give ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies